Polyrizon begins preclinical studies for seizure treatment

RAANANA, Israel - Polyrizon Ltd. (NASDAQ:PLRZ), a biotech firm in the development stage, has announced the initiation of preclinical studies for a new intranasal delivery of Benzodiazepines (BZDs), aimed at treating acute repetitive seizures (ARS) and status epilepticus. This move leverages their proprietary hydrogel technology platform, with the studies being conducted in collaboration with Professor Fabio Sonvico from the University of Parma, a member of Polyrizon’s Scientific Advisory Board. The company, currently trading at $0.35, maintains a strong liquidity position with a current ratio of 10.16, according to InvestingPro data.

Epilepsy, a neurological disorder affecting around 50 million people globally, often requires prompt intervention to manage acute seizures. BZDs, the first-line drugs for such emergencies, work by enhancing the GABA-A receptor in the central nervous system. Polyrizon’s intranasal delivery method promises to provide a rapid and accessible option for administering these medications outside of hospital settings, allowing emergency responders, caregivers, and patients themselves to manage seizures more effectively.

The global market for acute repetitive seizures was valued at approximately USD 3.15 billion in 2024 and is expected to grow at a compound annual growth rate (CAGR) of 12.7% from 2025 to 2030. Polyrizon’s Trap and Target™ (T&T) platform is at the forefront of this research, aiming to offer a patient-friendly solution that could significantly impact the way seizures are treated in emergency scenarios.

Tomer Izraeli, CEO of Polyrizon, expressed optimism about the potential of their intranasal delivery platform to offer a faster, safer, and more accessible solution for managing acute seizures, especially in out-of-hospital environments.

Polyrizon specializes in the development of medical device hydrogels for nasal sprays, designed to create a barrier against viruses and allergens in the nasal cavity. Their Capture and Contain™ (C&C) hydrogel technology is a key component of this innovative approach to drug delivery.

It is important to note that the information in this article is based on a press release statement and that forward-looking statements involve risks and uncertainties. Actual results may differ from those projected by Polyrizon, and the company is not responsible for the content of third-party websites referenced in the press release. Investors should note that Polyrizon’s next earnings report is scheduled for May 21, 2025. For detailed financial analysis and real-time updates, consider subscribing to InvestingPro.

In other recent news, Polyrizon Ltd. reported the successful completion of a preliminary safety study for its PL-14 Allergy Blocker, a nasal gel spray designed to protect against allergens. The study demonstrated strong local tolerability, with no significant differences in tissue viability or inflammatory responses compared to control groups. This milestone supports Polyrizon’s regulatory strategy as it prepares for a pre-submission meeting with the FDA, with clinical trials anticipated to begin in late 2025 or early 2026. Additionally, Polyrizon has secured approximately $17 million through a private placement with institutional investors, facilitated by Aegis Capital Corp. The funds are intended for general corporate purposes and working capital. In a strategic move, Polyrizon has also partnered with a branding consultancy to establish a brand identity for its Capture and Contain™ hydrogel technology. This collaboration is aligned with the company’s clinical and regulatory milestones. Polyrizon continues to focus on developing its Trap and Target™ technology for nasal delivery of active pharmaceutical ingredients, which remains in the pre-clinical stage.

This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.